3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
33
Docetaxel
10
Nivolumab
9
Paclitaxel
6
Trastuzumab
5
Gemcitabine
5
Cetuximab
5
Carboplatin
5
Capecitabine
5
Fulvestrant
4
Cyclophosphamide
4
spartalizumab
3
poly ICLC
3
durvalumab
3
avelumab
3
Oxaliplatin
3
Leucovorin
3
Ipilimumab
3
Fluorouracil
3
Cisplatin
3
Biopsy
3
zimberelimab
2
tremelimumab
2
palbociclib
2
obinutuzumab
2
lenvatinib
2
cemiplimab
2
budigalimab
2
Vorinostat
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
bemarituzumab
×
Breast
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled